This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1,054,000 Nuvalent shares in Q4, an estimated $103.93 million trade based on quarterly average pricing. The transaction is a notable large-volume disposition that may exert selling pressure on Nuvalent shares but is presented as a factual, one-off portfolio move without additional context on intent or impact.

Analysis

Vestal Point Capital sold 1,054,000 Nuvalent shares in Q4, an estimated $103.93 million trade based on quarterly average pricing. The transaction is a notable large-volume disposition that may exert selling pressure on Nuvalent shares but is presented as a factual, one-off portfolio move without additional context on intent or impact.